Wesley DeHaan

972 total citations
19 papers, 745 citations indexed

About

Wesley DeHaan is a scholar working on Nephrology, Pulmonary and Respiratory Medicine and Rheumatology. According to data from OpenAlex, Wesley DeHaan has authored 19 papers receiving a total of 745 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Nephrology, 8 papers in Pulmonary and Respiratory Medicine and 8 papers in Rheumatology. Recurrent topics in Wesley DeHaan's work include Inhalation and Respiratory Drug Delivery (8 papers), Gout, Hyperuricemia, Uric Acid (8 papers) and Urticaria and Related Conditions (7 papers). Wesley DeHaan is often cited by papers focused on Inhalation and Respiratory Drug Delivery (8 papers), Gout, Hyperuricemia, Uric Acid (8 papers) and Urticaria and Related Conditions (7 papers). Wesley DeHaan collaborates with scholars based in United States, Sweden and Canada. Wesley DeHaan's co-authors include Warren H. Finlay, Rita O. P. Fung, Kwok Hung Chan, GM Leung, Donald K. Milton, Benjamin J. Cowling, James McDevitt, M. Patricia Fabian, Alan Kivitz and Edgar Matida and has published in prestigious journals such as Nature Communications, PLoS ONE and Annals of the Rheumatic Diseases.

In The Last Decade

Wesley DeHaan

19 papers receiving 715 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wesley DeHaan United States 7 563 130 121 103 88 19 745
Kristina A. Davis United States 8 602 1.1× 214 1.6× 32 0.3× 54 0.5× 115 1.3× 9 893
Xiaojian Xie China 7 489 0.9× 33 0.3× 65 0.5× 131 1.3× 90 1.0× 12 605
Robert M. Eninger United States 8 394 0.7× 68 0.5× 139 1.1× 28 0.3× 148 1.7× 14 569
Jonathan V. Szalajda United States 8 477 0.8× 74 0.6× 33 0.3× 34 0.3× 102 1.2× 12 576
Yinge Qian United States 8 328 0.6× 56 0.4× 100 0.8× 25 0.2× 143 1.6× 11 466
Alejandro Posada Colombia 7 301 0.5× 93 0.7× 26 0.2× 61 0.6× 55 0.6× 12 415
Eline Dehandschoewercker France 2 494 0.9× 19 0.1× 51 0.4× 142 1.4× 58 0.7× 3 631
Xiuhua April United States 14 391 0.7× 21 0.2× 75 0.6× 56 0.5× 14 0.2× 38 544
Malin Alsved Sweden 11 330 0.6× 24 0.2× 18 0.1× 36 0.3× 119 1.4× 17 509
Sharon L. Norris United States 15 183 0.3× 36 0.3× 18 0.1× 32 0.3× 67 0.8× 35 674

Countries citing papers authored by Wesley DeHaan

Since Specialization
Citations

This map shows the geographic impact of Wesley DeHaan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wesley DeHaan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wesley DeHaan more than expected).

Fields of papers citing papers by Wesley DeHaan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wesley DeHaan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wesley DeHaan. The network helps show where Wesley DeHaan may publish in the future.

Co-authorship network of co-authors of Wesley DeHaan

This figure shows the co-authorship network connecting the top 25 collaborators of Wesley DeHaan. A scholar is included among the top collaborators of Wesley DeHaan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wesley DeHaan. Wesley DeHaan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
3.
4.
5.
Kivitz, Alan, Wesley DeHaan, Justin Park, et al.. (2023). Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110). Rheumatology and Therapy. 10(4). 825–847. 16 indexed citations
6.
Baraf, Herbert S. B., Alan Kivitz, Sheldon S. Leung, et al.. (2023). LB0002 SAFETY & EFFICACY OF SEL-212 IN PATIENTS WITH GOUT REFRACTORY TO COVENTIONAL TREATMENT: OUTCOMES FROM TWO RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE III STUDIES. Annals of the Rheumatic Diseases. 82. 200–201. 3 indexed citations
7.
Baraf, Herbert S. B., Puja Khanna, Alan Kivitz, et al.. (2023). The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout. Lara D. Veeken. 63(4). 1058–1067. 16 indexed citations
8.
Kivitz, Alan, et al.. (2022). Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia. Nature Communications. 13(1). 272–272. 40 indexed citations
9.
Kuehl, Philip J., Ramesh Chand, Jacob D. McDonald, David L. Hava, & Wesley DeHaan. (2019). Pulmonary and Regional Deposition of Nebulized and Dry Powder Aerosols in Ferrets. AAPS PharmSciTech. 20(6). 242–242. 6 indexed citations
10.
11.
12.
Kivitz, Alan, et al.. (2018). FRI0234 Sel-212: selective mitigation of anti-drug antibodies against pegsiticase to control serum uric acid in hyperuricemic subjects. Annals of the Rheumatic Diseases. 77. 658–658. 2 indexed citations
13.
DeHaan, Wesley, et al.. (2012). Inhaled Calcium Based Dry Powder Enhances Whole Lung Mucociliary Clearance In Sheep. A2862–A2862. 1 indexed citations
14.
15.
Fabian, M. Patricia, James McDevitt, Wesley DeHaan, et al.. (2008). Influenza Virus in Human Exhaled Breath: An Observational Study. PLoS ONE. 3(7). e2691–e2691. 395 indexed citations
16.
Clarke, Robert W., et al.. (2005). Pulmonary delivery of anti-contagion aerosol to diminish exhaled bioaerosols and airborne infectious disease. American Journal of Infection Control. 33(5). e85–e85. 6 indexed citations
17.
DeHaan, Wesley & Warren H. Finlay. (2003). Predicting extrathoracic deposition from dry powder inhalers. Journal of Aerosol Science. 35(3). 309–331. 115 indexed citations
18.
Matida, Edgar, Wesley DeHaan, Warren H. Finlay, & Carlos F. Lange. (2003). Simulation of Particle Deposition in an Idealized Mouth with Different Small Diameter Inlets. Aerosol Science and Technology. 37(11). 924–932. 41 indexed citations
19.
DeHaan, Wesley & Warren H. Finlay. (2001). In Vitro Monodisperse Aerosol Deposition in a Mouth and Throat with Six Different Inhalation Devices. Journal of Aerosol Medicine. 14(3). 361–367. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kristina A. Davis Breakdown of academic impact, for papers by Xiaojian Xie Breakdown of academic impact, for papers by Robert M. Eninger Breakdown of academic impact, for papers by Jonathan V. Szalajda Breakdown of academic impact, for papers by Yinge Qian Breakdown of academic impact, for papers by Alejandro Posada Breakdown of academic impact, for papers by Eline Dehandschoewercker Breakdown of academic impact, for papers by Xiuhua April Breakdown of academic impact, for papers by Malin Alsved Breakdown of academic impact, for papers by Sharon L. Norris
Rankless by CCL
2026